Compare CGNX & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGNX | QGEN |
|---|---|---|
| Founded | 1981 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 8.7B |
| IPO Year | 1994 | 1998 |
| Metric | CGNX | QGEN |
|---|---|---|
| Price | $63.68 | $43.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $57.91 | $45.76 |
| AVG Volume (30 Days) | 1.9M | ★ 2.2M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | 0.64% | ★ 7.17% |
| EPS Growth | ★ 9.68 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.52 | $8.18 |
| Revenue Next Year | $8.63 | $5.71 |
| P/E Ratio | $90.39 | ★ $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.60 | $32.53 |
| 52 Week High | $72.88 | $57.82 |
| Indicator | CGNX | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 50.36 | 61.05 |
| Support Level | $62.63 | $39.08 |
| Resistance Level | $70.53 | $42.33 |
| Average True Range (ATR) | 2.84 | 0.85 |
| MACD | 0.47 | -0.07 |
| Stochastic Oscillator | 52.61 | 89.09 |
Cognex Corp provides machine vision products that help automate manufacturing processes. The firm's products include vision software, vision systems, vision sensors, and ID products. Vision software combines vision tools with a customer's cameras and peripheral equipment and can help with several vision tasks, including part location, identification, measurement, and robotic guidance. Vision systems combine a camera, processor, and vision software into a single package. Vision sensors deliver simple, low-cost solutions for common vision applications, such as checking the size of parts. Geographically, it operates in United states, Europe, Greater China and others. Cognex generates the maximum proportion of its sales in the United States and Europe.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).